{
    "clinical_study": {
        "@rank": "38605", 
        "acronym": "CERAMIC", 
        "arm_group": {
            "arm_group_label": "Post-Campylobacter", 
            "description": "Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured"
        }, 
        "biospec_descr": {
            "textblock": "Stool (Faeces) Whole Blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The principal research objective is to determine the impact of antibiotic use on the risk of\n      developing long term bowel symptoms after infection with the germ Campylobacter."
        }, 
        "brief_title": "Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Campylobacter Infections", 
            "Irritable Bowel Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Campylobacter Infections", 
                "Enteritis", 
                "Intestinal Diseases", 
                "Irritable Bowel Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The secondary research objectives are:\n\n        -  To investigate how the particular strain of the Campylobacter germ that causes the\n           infection, and the strength of the immune response that it stimulates in the bowel,\n           affect the risk of long term bowel symptoms.\n\n        -  To explore what changes occur after Campylobacter infection in the bacteria that\n           usually live in the large bowel (microbiota) and the chemicals that they produce\n           (short-chain fatty acids) when they digest nutrients. We will look for differences\n           between people who recover fully and people who have long term bowel symptoms."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18\n\n          -  Clinical syndrome suggestive of intestinal infection, including symptoms such as new\n             onset of abdominal pain, vomiting, diarrhoea, blood in stools, fever\n\n          -  Submission of stool sample to Nottingham University Hospitals Microbiology Laboratory\n             for investigation of these symptoms\n\n          -  Campylobacter sp. cultured by selective media (standard clinical practice) from this\n             stool sample\n\n        Exclusion Criteria:\n\n          -  Pregnancy declared by the candidate\n\n          -  History declared by the candidate of pre-existing gastrointestinal disorder,\n             including but not limited to:\n\n               -  Inflammatory Bowel Disease\n\n               -  Coeliac Disease\n\n               -  Pancreatitis\n\n               -  Gallstone disease (biliary colic, cholecystitis)\n\n               -  Diverticulitis\n\n               -  Cancer of the gastrointestinal tract\n\n               -  Irritable Bowel Syndrome\n\n          -  Reported history of previous resection of any part of the gastrointestinal tract\n             other than appendix or gallbladder\n\n          -  Intestinal stoma\n\n          -  Habitual use of opiate analgesics likely to alter bowel function e.g. morphine\n\n          -  Use of antibiotics in the preceding four weeks other than for treatment of index\n             infection.\n\n          -  Use of purgative products/ high dose laxatives for bowel preparation in the four\n             weeks prior to index infection.\n\n          -  Any condition where the candidate is likely to require a course of antibiotics in the\n             next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract\n             infection, lower limb ulceration\n\n          -  Inability to complete the symptom questionnaires e.g. cognitive dysfunction limiting\n             memory and understanding\n\n          -  Declared participation in any medical trials in the past 3 months\n\n          -  Anyone who in the opinion of the investigator is unlikely to be able to comply with\n             the protocol e.g. cognitive dysfunction, chaotic lifestyle related to substance abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adults in the Nottinghamshire area with no previous history of gastrointestinal disorder\n        or surgical resection. Those who submit a stoo lsample from which Campylobacter spp. is\n        cultured will be invited to take part."
            }
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040922", 
            "org_study_id": "13091", 
            "secondary_id": "13/EM/0310"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Antibiotics", 
            "Campylobacter", 
            "Diarrhoea", 
            "Enteritis", 
            "Microbiota", 
            "Calprotectin"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "link": {
            "description": "Departmental website", 
            "url": "http://www.nddcbru.org.uk"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "zip": "NG7 2UH"
                }, 
                "name": "University of Nottingham"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Study of the Role of Antibiotics, Inflammation and Changes in Microbiota in the Development of Post-infective Bowel Dysfunction Following Infection With Campylobacter Jejuni or Coli", 
        "overall_official": [
            {
                "affiliation": "University of Nottingham", 
                "last_name": "Robin C Spiller, MSc MD FRCP", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Nottingham", 
                "last_name": "Giles AD Major, BM BCh MRCP", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Nottingham University Hospitals NHS Trust", 
                "last_name": "Mathew Diggle, MSc PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of Nottingham", 
                "last_name": "Richard Puleston, MBBS PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "King's College London", 
                "last_name": "Miranda Lomer, PhD RD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: National Institute for Health Research", 
                "United Kingdom: National Health Service"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This will be defined by response to the question \"have your bowels returned to normal since your Campylobacter infection?\"", 
            "measure": "Yes/ no: Post-Infective bowel dysfunction (PI-BD)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after microbiological diagnosis of infection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040922"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Symptoms meeting Rome III criteria for Irritable Bowel Syndrome (other than 6 month duration)", 
            "measure": "Yes/ No: Post-Infective irritable bowel syndrome (PI-IBS)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after microbiological diagnosis of infection"
        }, 
        "source": "University of Nottingham", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Nottingham University Hospitals NHS Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Department of Health, United Kingdom", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "King's College London", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Helsinki University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Nottingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}